A message from Stocks.News Shuttle Pharmaceuticals (NASDAQ: SHPH) Is Leveraging AI, Precision Radiotherapy, and Novel Cancer Therapies to Target Multi-Billion-Dollar Markets. 
With an FDA-designated orphan drug candidate, advancing Phase 2 clinical trials, AI-driven drug discovery, and next-generation diagnostics, SHPH is positioning itself at the forefront of innovation in cancer treatment! Greetings All, The oncology sector has emerged as one of the most critical and dynamic areas in modern medicine, driven by the growing global cancer burden and the urgent need for more effective, targeted therapies. With millions of new cancer diagnoses each year and survival outcomes still limited for many aggressive diseases, innovation in cancer treatment has become a top priority across the pharmaceutical industry. As the industry looks ahead, 2026 is shaping up to be a pivotal year for pharmaceutical and biotechnology companies focused on oncology. Clinical milestones, expanding markets, and the integration of advanced technologies such as artificial intelligence are accelerating development timelines and opening new pathways to improve patient outcomes. Shuttle Pharmaceuticals (NASDAQ: SHPH) stands out in this landscape by combining an FDA-designated orphan drug candidate, advancing Phase 2 clinical development, AI-powered drug discovery capabilities, and next-generation diagnostics—all focused on enhancing the effectiveness of radiation therapy in some of the most aggressive and underserved cancers. Company Snapshot Shuttle Pharmaceuticals (NASDAQ: SHPH) is focused on pioneering precision medicine approaches designed to enhance radiation therapy, prolong survival, and improve quality of life for cancer patients. With a core emphasis on radiation sensitizers, diagnostics, and innovative therapeutic candidates, the company is addressing major unmet needs across oncology, particularly in aggressive cancers such as glioblastoma and prostate cancer. As cancer incidence continues to rise globally, SHPH positions itself at the center of an expanding demand for more effective and targeted treatment solutions. AI-Powered Innovation Through Molecule.ai Acquisition SHPH recently reached a significant strategic milestone by acquiring the AI health platform Molecule.ai. This transaction expands the company’s technological capabilities and strengthens its mission to advance precision radiotherapy solutions. Molecule.ai’s platform brings advanced molecular modeling and predictive analytics tools that are expected to enhance Shuttle’s drug discovery and development pipeline. The planned deployment of next-generation agentic AI systems is expected to support greater efficiency, deeper insights, and accelerated innovation across the company’s development pipeline—potentially pushing therapeutic development further than either organization could achieve independently. Lead Program Focus: Ropidoxuridine (IPdR) and Radiation Sensitization At the core of Shuttle Pharmaceuticals’ pipeline is Ropidoxuridine (IPdR), the company’s lead candidate and a radiation sensitizer designed for use in combination with radiation therapy. IPdR is being developed to treat glioblastoma, a deadly and aggressive brain tumor with no known cure. Standard treatments for glioblastoma—surgery, radiotherapy, and chemotherapy—are associated with high recurrence rates and poor outcomes, underscoring the urgent need for new therapeutic approaches. Importantly, IPdR has received Orphan Drug Designation from the U.S. Food and Drug Administration, which may provide marketing exclusivity upon first FDA approval for the treatment of glioblastoma. This designation highlights both the seriousness of the disease and the potential clinical importance of SHPH’s approach. Advancing Through Phase 2 Development SHPH has made notable clinical progress with the commencement of its Phase 2 clinical trial evaluating Ropidoxuridine in patients with glioblastoma. More than one-third of the initial randomized portion of enrollment has already been completed, with a target to finalize enrollment in the coming year. According to Anatoly Dritschilo, MD, Chief Scientific Officer and Chairman, this trial holds critical importance for the radiation therapy industry, aiming to enhance cure rates, extend survival, and improve quality of life through the use of radiation sensitizers. Beyond IPdR: A Broader Oncology Pipeline In addition to Ropidoxuridine, SHPH is developing three additional therapeutic candidates targeting solid tumors, including breast cancer, lung cancer, and multiple myeloma. These include SP-2-225, a selective HDAC6 inhibitor involved in antigen presentation; SP-1-303, a Class I HDAC inhibitor with preferential efficacy against ER-positive cancers; and SP-1-161, a candidate that activates the ATM gene, which plays a critical role in DNA damage response and repair. Together, these programs reflect a diversified approach to addressing multiple cancer pathways. Precision Tools for Radiation Therapy SHPH is also advancing next-generation diagnostics through its Shuttle Diagnostics initiative. The PC-Rad Test is being developed to predict outcomes following radiation therapy for localized prostate cancer, offering clinicians a way to guide treatment decisions with greater confidence. In parallel, the PSMA-B Ligand is being developed as a theranostic molecule, enabling both diagnosis and treatment for metastatic prostate cancer. This approach introduces a new way to measure and predict radiation therapy success with increased precision. Market Opportunity: The company operates within rapidly expanding markets. The global oncology market, valued at $321.19 billion in 2024, is projected to reach $903.81 billion by 2034, while the radiation therapy market is expected to grow from $7.86 billion in 2025 to $12.93 billion by 2034. Demand for radiation sensitizers is projected to grow by more than 22% over the next five years, reflecting the increasing need to enhance radiotherapy effectiveness. In prostate cancer and glioblastoma specifically, diagnostic and treatment markets are also expanding, highlighting significant opportunities for innovative therapies like IPdR and precision diagnostic tools such as PSMA-B Ligand and PC-Rad. Financial and Strategic Positioning SHPH reports having more cash than total debt, which may strengthen its financial flexibility and reduce balance-sheet risk. The company is also supported by strategic partnerships and collaborations with leading medical and cancer research institutions, including Georgetown University Medical Center, UNC Medical Center, UVA Cancer Center, John Theurer Cancer Center, Allegheny Health Network Cancer Institute, and Miami Cancer Institute—supporting clinical development and research execution. The Bottom Line As the oncology sector continues to expand and the demand for more effective cancer treatments intensifies, Shuttle Pharmaceuticals (NASDAQ: SHPH) is emerging as a company worth close attention heading into 2026. With an FDA-designated orphan drug candidate advancing through Phase 2 development, a growing pipeline of targeted therapies, expanding diagnostic capabilities, and the strategic integration of AI to enhance drug discovery, SHPH brings together multiple catalysts that could shape its trajectory in the coming years. Positioned at the intersection of precision radiotherapy, innovation, and large, growing oncology markets, Shuttle Pharmaceuticals stands out as a biotech stock to watch in 2026 and beyond as the next wave of cancer treatment advancements unfolds. | 
